CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
MV-CHIK +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03101111
NCT03101111Phase 2Completed
CompareCT.gov

Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area

Themis Bioscience GmbH·interventional·Posted Apr 4, 2017·Updated Jul 19, 2021

In Brief

A Phase 2 clinical trial evaluating MV-CHIK and MMR-vaccine for Chikungunya. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed. MV-CHIK will be compared to the commercially available MMR vaccine. 80% of the subjects will receive MV-CHIK; 20% will receive MMR vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya
CountriesPuerto Rico
CollaboratorsWalter Reed Army Institute of Research (WRAIR)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 4, 2017
Enrollment StartAug 9, 2017
Primary CompletionApr 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.2 years ago

Interventions

MV-CHIKbiological

Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose

MMR-vaccinebiological

Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose